NeuroMind BioPharma

Industry News

This Company is Working on A Drug that Will Make LSD Less Trippy

While trying to understand what makes the psychedelic drug LSD work, Dr. Mattias Liechti, head of the Liechti Laboratory at the University of Basel Hospital, stumbled onto something unexpected. During his research, he found a substance that seemed to abort the hallucinogenic effects of LSD within 20 to 30 minutes. MindMed, a pharmaceutical company focused […]

This Company is Working on A Drug that Will Make LSD Less Trippy Read More »

NeuroMind BioPharma Receives FDA Type C Meeting Response for Project Lucy Phase 2b Clinical Trial

MindMed Finalizes Clinical Development Approach for LSD Targeting Generalized Anxiety Disorder as Initial Indication MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading clinical stage psychedelic medicine company, announces receipt of Type C Meeting Responses from FDA leading to the finalization of the Company’s clinical development approach for Project Lucy by selecting Generalized Anxiety Disorder

NeuroMind BioPharma Receives FDA Type C Meeting Response for Project Lucy Phase 2b Clinical Trial Read More »